🧾 What This Document Is

This is a preliminary proxy statement (PRE 14A) for Savara Inc. Think of it as a company's official "meeting invitation and agenda" sent to its owners (stockholders). It explains what will be voted on at the upcoming annual meeting and provides the information needed to make informed decisions. The meeting is virtual on June 4, 2026.

🏢 What The Company Does

👉 In simple terms, Savara is a biopharmaceutical company focused on developing treatments for rare respiratory diseases. Their lead product is molgramostim inhalation solution (MOLBREEVI), a potential therapy for autoimmune pulmonary alveolar proteinosis (PAP), a serious lung condition. They are currently a clinical-stage company preparing for a potential commercial launch.

🚀 Key Moves & Financial Prep

Savara is in a pivotal phase, shifting from development to a commercial company. They've taken major steps to prepare financially:

• Completed a $149.5 million equity financing to strengthen their balance sheet.
• Entered a $75 million royalty funding agreement with RTW to support the potential launch of MOLBREEVI.
• Amended their debt facility to allow for up to $75 million in additional funding once they get FDA approval. 👉 These moves show they are proactively securing the cash needed to launch and market their drug if approved.

📦 What's Being Voted On

Stockholders will vote on five main proposals:

1. Elect six directors to the Board.
2. Increase authorized shares from 300 million to 600 million. This gives the company flexibility for future financing or employee incentives.
3. Add 18.9 million shares to their employee stock incentive plan to attract and retain talent.
4. Ratify RSM US LLP as their auditor for 2026.
5. Hold an advisory vote on executive compensation ("Say-on-Pay").

👥 The People In Charge

The Board and executive team are highlighted to show governance and leadership:

• Board of Directors: Six nominees, chaired by CEO Matthew Pauls. The board includes experts in biopharma, finance, and commercialization. Five of the six are deemed independent.
• Executive Team: Led by CEO Matthew Pauls, the C-suite includes executives with deep experience in commercial launches, clinical development, and finance, all crucial for the company's next phase.

🔮 Regulatory Path & Timeline

The company's near-term future hinges on regulatory decisions for MOLBREEVI:

• U.S. (FDA): Under Priority Review. Action Date: August 22, 2026.
• EU (EMA): Decision expected in Q1 2027.
• UK (MHRA): Decision expected in Q4 2026. 👉 The upcoming FDA date is the most critical near-term catalyst for the company.

💡 Why This Matters to Investors

This document reveals a company at a critical inflection point. The proposals are standard but necessary for operational flexibility. More importantly, the messaging underscores that Savara is financially preparing for a product launch and has a clear, near-term regulatory timeline. The outcome of the FDA review will likely be the most significant driver of the company's value in 2026.

⚠️ Key Risks

• Regulatory Risk: The core risk is that MOLBREEVI may not receive approval from the FDA or other regulators.
• Commercialization Risk: Even if approved, successfully launching a new drug in a rare disease market is complex and costly.
• Financial Risk: The company is still pre-revenue and will rely on its recent financings and future cash flow to fund operations.

🧠 The Analogy

Savara is like a startup restaurant that has spent years perfecting a single, unique recipe (MOLBREEVI). It has just secured loans and investors (the equity/debt financing) to renovate the space and hire staff (commercial launch preparations). Now, it's waiting for the final health inspection (FDA approval) before it can open its doors to customers. This meeting is where the owners review the plans and budget for that big opening.

🧩 Final Takeaway

Savara is a biotech company laser-focused on getting its lead drug, MOLBREEVI, approved and launched. This proxy meeting is about securing the corporate tools (shares, auditor, director oversight) needed for that journey. The August 2026 FDA decision is the make-or-break event that will determine the company's immediate future.